Radiation Therapy for Mesothelioma

Radiation Therapy for Mesothelioma
Primary Techniques	IMRT, Proton Therapy
SMART Protocol	25 Gy / 5 fractions
Adjuvant Dose	45–54 Gy typical
Palliative Dose	20–36 Gy typical
Best Median OS	65.9 months (SMART)
Tract Irradiation	Not recommended
Key Risk	Radiation pneumonitis
ASCO Guideline	Updated 2025
Free Case Review →

Radiation therapy for malignant pleural mesothelioma has evolved from a purely palliative tool into a component of multimodality curative-intent treatment strategies. Despite historical perceptions of radioresistance, laboratory studies demonstrate that mesothelioma cell lines exhibit sensitivity comparable to or better than non-small cell lung cancer. The principal challenge is not tumor biology but anatomy: the pleural surface is a large, complex target that encases radiosensitive organs including the lungs, heart, esophagus, liver, and kidneys. Advances in intensity-modulated radiation therapy (IMRT), pencil-beam scanning proton therapy, and novel sequencing strategies such as the SMART protocol have expanded the therapeutic window. This page covers all clinical applications of radiation in mesothelioma, including adjuvant therapy after surgery, the SMART protocol, IMRT and proton techniques, palliative radiation, prophylactic tract irradiation, side effect management, and ongoing clinical trials as of 2026.

Key radiation therapy insights for mesothelioma:

• Not truly radioresistant — lab studies show mesothelioma sensitivity comparable to NSCLC
• SMART protocol breakthrough — 65.9-month median survival in epithelioid, node-negative patients
• IMRT precision — intensity-modulated technique enables hemithoracic treatment with organ-sparing
• Proton therapy advantage — reduces heart dose from 25 Gy (IMRT) to just 6 Gy
• 60–80% palliative relief — most patients report meaningful symptom improvement
• Tract irradiation abandoned — no longer recommended after 4 negative randomized trials including 374-patient PIT study
• Critical dose limit — combined mean lung dose must stay below 20 Gy to prevent fatal pneumonitis
• Peritoneal role minimal — CRS-HIPEC preferred; radiation plays limited role in peritoneal disease
• Active clinical trials — SMARTER, SYSTEMS-2, and MESO-PRIME testing dose escalation and immunotherapy combinations

Key Facts

Key Facts: Radiation Therapy for Mesothelioma

Mesothelioma is not truly radioresistant: In vitro studies show similar or improved radiosensitivity compared to NSCLC cell lines SMART protocol best outcomes: 65.9-month median survival in epithelioid, node-negative patients — the first mesothelioma trial to exceed 5-year median survival Adjuvant IMRT after P/D: Produces median overall survival of 19–33 months with modern dose constraints Palliative response rate: 60–80% of patients report symptom relief after palliative radiation Prophylactic tract irradiation: No longer recommended based on 4 negative randomized trials including the 374-patient PIT trial Proton therapy advantage: Reduces heart mean dose from 25 Gy (IMRT) to 6 Gy, and contralateral lung mean dose from 4.6 Gy to 0.4 Gy IMRT dose constraints: Combined mean lung dose must remain below 20–21 Gy with V20 below 37–40% to prevent fatal pneumonitis Peritoneal mesothelioma: Radiation plays a minimal role; CRS-HIPEC is the primary curative approach Key dose-limiting toxicity: Radiation pneumonitis, with rates varying from 6% (proton) to 46% (early post-EPP IMRT series) Active clinical trials: SMARTER (dose escalation), SYSTEMS-2 (palliative optimization), MESO-PRIME (radiation + immunotherapy)

What Role Does Radiation Play in Mesothelioma Treatment?

Radiation therapy serves multiple roles in mesothelioma management, from curative-intent multimodal treatment to symptom palliation. Understanding the biological basis of radiation response in mesothelioma is essential for appreciating both its potential and its limitations.

Debunking the Radioresistance Myth

Mesothelioma was historically considered a radioresistant malignancy because early series using conventional radiation techniques failed to control residual disease after surgery. However, this perceived resistance reflects technical limitations rather than inherent tumor biology. In vitro studies by Carmichael and colleagues and Hakkinen and colleagues demonstrated that mesothelioma cell lines have radiosensitivity comparable to or better than NSCLC cell lines. Furthermore, mesothelioma likely has a low alpha/beta ratio given its non-squamous histology and slow proliferation, suggesting it may be more sensitive to increased dose per fraction (hypofractionation).

Clinical evidence supports this conclusion. In a retrospective series of 189 patients from the Netherlands, a 4 Gy per fraction palliative regimen yielded a higher local response rate (50%) than regimens using fractions below 4 Gy (39%). The difficulty of assessing radiation response using standard RECIST criteria in a disease with sheet-like pleural growth patterns has further obscured the tumor's true radiosensitivity.

Current Applications

Radiation use in mesothelioma encompasses several distinct clinical scenarios: adjuvant radiation after surgical cytoreduction, neoadjuvant radiation before surgery (the SMART protocol), palliative symptom management for chest wall pain and local tumor invasion, and experimental combinations with immunotherapy. Prophylactic tract irradiation, once widely practiced, is no longer recommended based on multiple negative randomized trials.

What Is Adjuvant Radiation After Surgery?

Adjuvant radiation following surgical cytoreduction aims to sterilize microscopic residual disease along the pleural surfaces. The approach, technique, and complexity differ substantially depending on whether the patient underwent extrapleural pneumonectomy (EPP) or lung-sparing pleurectomy/decortication (P/D).

Post-EPP Hemithoracic Radiation

Adjuvant radiation following EPP was the original radical radiotherapy approach for mesothelioma. The absence of the ipsilateral lung simplified field design, allowing broad-field coverage of the entire hemithorax. However, the SAKK 17/04 randomized phase II trial tested post-EPP hemithoracic radiation (median 55.9 Gy) versus observation after induction chemotherapy and EPP. With 54 patients randomized, there was no significant difference in locoregional relapse-free survival (median 9.4 versus 7.6 months) or overall survival (19.3 versus 20.8 months). Notably, only 1 of 27 irradiated patients had a local recurrence, suggesting local efficacy but overall futility from distant failures outside the radiation field.

Post-P/D Radiation: The Intact-Lung Challenge

With the shift from EPP toward lung-sparing P/D, radiation delivery became considerably more complex due to the presence of two intact radiosensitive lungs. The IMPRINT trial (Rimner and colleagues, Journal of Clinical Oncology, 2016) was a pivotal multicenter phase II study of hemithoracic IMRT after chemotherapy with or without P/D. The planned dose was 50.4 Gy, with strict dose constraints including combined mean lung dose at or below 21 Gy and combined lung V20 at or below 37–40%. Of 27 evaluable patients, only 2 (7%) developed grade 3 pneumonitis, with no grade 4 or 5 pneumonitis observed.

A 2025 systematic review of adjuvant radiotherapy after P/D encompassing 11 level II studies confirmed that IMRT using 45–54 Gy produced median overall survival of 19–33 months (mean 23.6 months) with grade 2 or higher pneumonitis rates of 2–30% (mean 17.6%).

Dose Constraint	Post-EPP (Contralateral Lung)	Post-P/D (Bilateral Lungs)
Mean Lung Dose	Less than 8.5 Gy	20–21 Gy or less
Lung V20	Less than 10%	37–40% or less
Lung V5	Less than 60%	Minimize
Typical Prescription Dose	45–54 Gy	45–50.4 Gy

What Is the SMART Protocol?

The SMART protocol (Surgery for Mesothelioma After Radiation Therapy) represents one of the most innovative approaches to mesothelioma treatment, inverting the conventional treatment sequence by delivering radiation before surgery rather than after. Developed by Dr. Marc de Perrot and colleagues at Princess Margaret Cancer Centre, University of Toronto, this protocol has produced the longest median survival documented in any mesothelioma multimodal trial.

Rationale

The SMART approach addresses several limitations of conventional post-operative radiation. Pre-operative radiation sterilizes microscopic disease at the pleural surface before surgery, reducing the risk of tumor cell spillage during operative manipulation. Because the irradiated lung is removed within days, radiation pneumonitis cannot develop in the treated lung. Patients complete the entire local therapy program within 2–3 weeks, avoiding the high attrition rates seen with post-operative radiation sequencing. Additionally, hypofractionated radiation may trigger an immunogenic response that enhances systemic tumor control.

Protocol Details

Patients receive accelerated hemithoracic IMRT with 25 Gy in 5 daily fractions over 1 week to the entire ipsilateral hemithorax, including pleural reflections and intervention tract sites. A simultaneous integrated boost delivers 30 Gy to the gross tumor volume identified by PET/CT. EPP is performed within 1 week (typically 4–10 days) of completing radiation. Adjuvant chemotherapy is offered selectively to patients with pathologically positive lymph nodes.

Published Outcomes

The definitive phase 2 results published by Cho and colleagues in The Lancet Oncology (January 2021) enrolled 102 patients between November 2008 and October 2019, with 96 eligible patients treated. The overall cohort achieved a median overall survival of 36 months. The epithelioid, node-negative subgroup of 19 patients achieved an unprecedented 65.9-month median overall survival — the first multimodal radical surgery trial for mesothelioma to exceed a 5-year median survival. Disease-free survival for clinical stage T1-3N0M0 patients was 47 months. The biphasic subtype showed markedly worse outcomes with median OS of only 10 months. The 30-day surgical mortality was 0% in the de Perrot cohort, with 3 treatment-related deaths (4.8%) overall.

SMARTER Trial

The follow-on SMARTER study (NCT04028570) investigates dose escalation to the gross tumor volume for potential immunostimulatory properties, with maximum tolerated dose as the primary endpoint. Newer iterations are also exploring P/D in place of EPP within the SMART framework.

How Does IMRT Work for Mesothelioma?

Intensity-modulated radiation therapy uses computer-optimized multi-beam arrangements to conform dose to the complex pleural envelope while sparing organs at risk. In mesothelioma, this typically involves 6–9 coplanar beams or volumetric modulated arc therapy spanning 220–240 degrees to avoid beam entry through the contralateral lung. Four-dimensional CT simulation accounts for respiratory motion, and daily image guidance with cone-beam CT ensures accurate delivery.

Typical prescription doses range from 45 to 54 Gy in 1.8–2.0 Gy daily fractions, with some protocols using a simultaneous integrated boost to gross disease. NCCN guidelines recommend lung V20 below 35% and mean lung dose below 20 Gy to minimize the risk of radiation pneumonitis.

The transition from conventional radiation to IMRT improved outcomes significantly. Memorial Sloan Kettering/Mount Sinai retrospective data showed median overall survival of 20.2 months for IMRT compared to 12.3 months for conventional radiation techniques, reflecting the improved ability to deliver therapeutic doses while respecting normal tissue tolerances.

Is Prophylactic Tract Irradiation Still Recommended?

Mesothelioma is known to seed biopsy, port, and drain sites, with historical tract metastasis rates of 10–50%. Prophylactic irradiation of tracts became widespread after a landmark French trial by Boutin and colleagues (1995) randomized 40 patients to 21 Gy in 3 fractions versus no radiation, reporting 0% versus 40% tract metastases.

However, four subsequent randomized studies failed to reproduce this benefit. The PIT trial — the largest and most methodologically rigorous study with 374 patients — found no reduction in tract metastases with prophylactic radiation.

Trial	Patients	Dose	Result
Boutin et al. (1995)	40	21 Gy / 3 fractions	Positive: 0% vs 40%
Bydder et al. (2004)	~43	10 Gy / 1 fraction	No benefit
O'Rourke et al. (2007)	61	21 Gy / 3 fractions	No benefit
SMART Trial — Clive et al. (2016)	203	21 Gy / 3 fractions	No benefit
PIT Trial — Bayman et al. (2019)	374	21 Gy / 3 fractions	No benefit

This finding is now incorporated into the ERS/ESTS/EACTS/ESTRO guidelines and ESMO Clinical Practice Guidelines, both confirming that prophylactic tract irradiation is not justified in routine mesothelioma management. The lower modern tract metastasis rates compared to the 1995 Boutin data may reflect the concurrent use of systemic chemotherapy and immunotherapy.

How Is Palliative Radiation Used?

Palliative radiation remains the most common radiotherapy application in mesothelioma, used for chest wall pain, local tumor invasion, bone metastases, and occasionally brain metastases. Approximately 60–80% of mesothelioma patients report symptom relief after palliative radiation.

The SYSTEMS study (MacLeod and colleagues, Journal of Thoracic Oncology, 2015), the most contemporary prospective palliative radiation cohort, used 20 Gy in 5 fractions and demonstrated clinically significant pain improvement in 35% (14 of 40) of patients at 5 weeks.

Evidence supports a dose-response relationship. In a Dutch series of 189 patients, 36 Gy in 9 fractions produced a 50% local response rate compared to 39% for lower-dose regimens. Common palliative fractionation schedules include 8 Gy in a single fraction for uncomplicated bone metastases (recommended by ASCO guidelines), 20 Gy in 5 fractions (the SYSTEMS study regimen), 30 Gy in 10 fractions for more extensive disease, and 36 Gy in 6 fractions (being tested against 20 Gy in the SYSTEMS-2 randomized trial).

What Is the Role of Proton Beam Therapy?

The physical properties of proton beams — specifically the Bragg peak, which deposits the majority of dose at a defined depth with minimal exit dose — make proton therapy theoretically ideal for mesothelioma's complex pleural targets. Comparative planning studies demonstrate dramatic reductions in organ-at-risk doses compared to photon IMRT.

Dosimetric Parameter	Proton Therapy (PBS)	IMRT (Photons)
Contralateral lung mean dose	0.4 Gy	4.6 Gy
Heart mean dose	6.0 Gy	25.0 Gy
Liver mean dose	3.7 Gy	13.2 Gy
Contralateral lung V5	1.5%	27.5%
Esophagus mean dose	26.2 Gy	36.9 Gy

The largest published proton series (University of Pennsylvania, 16 patients) achieved durable local control in all patients at a median dose of 51.75 Gy, with no grade 3 or higher acute or late toxicities, only 6% grade 2 radiation pneumonitis, and improvement in ECOG performance score from 1.2 to 0.9. Rice and colleagues reported 90% local control at 1 and 2 years with proton therapy combined with photodynamic therapy after P/D, with no grade 3 or higher toxicities.

The International Particle Therapy Cooperative Group published a consensus statement on proton therapy in mesothelioma (Zeng and colleagues, 2021) to guide clinical practice and insurance approval. The NRG-LU006 trial permitted either photon IMRT or intensity-modulated proton therapy, reflecting growing acceptance of proton therapy for this disease.

How Is Radiation Used for Peritoneal Mesothelioma?

Radiation therapy plays a minimal role in peritoneal mesothelioma management. The primary curative-intent approach is cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC), which can produce median survival exceeding 5 years in selected patients.

Whole abdominal radiation therapy has historical precedent in abdominal malignancies but is rarely employed for peritoneal mesothelioma due to the dose-limiting toxicity of irradiating the entire peritoneal cavity, including the bowel, liver, and kidneys. NYU Langone Health notes that radiation may be applied to the entire abdominal area after surgery in select cases, but this remains uncommon. Palliative radiation may be used for focal symptomatic disease, particularly at port sites or areas of abdominal wall invasion.

What Are the Side Effects of Radiation Therapy?

Side effects of radiation therapy in mesothelioma vary substantially depending on the technique, dose, and clinical context. Understanding these risks is essential for treatment planning and informed decision-making.

Radiation Pneumonitis

Pneumonitis is the most clinically significant and potentially fatal toxicity of thoracic radiation in mesothelioma. Incidence varies dramatically by technique and setting. Early post-EPP IMRT series (Allen and colleagues, Dana-Farber/BWH) reported a 46% rate of fatal pneumonitis in 13 patients, which established the strict contralateral lung dose constraints now universally applied. Post-P/D IMRT using modern constraints (IMPRINT trial) reduced grade 3 pneumonitis to 7% with no fatalities. Proton therapy achieves the lowest rates, with only 6% grade 2 pneumonitis and no grade 3 or higher events at the University of Pennsylvania.

Key dosimetric predictors of severe pneumonitis include total lung V5, V10, V20, mean lung dose, total lung volume, and prior pneumonectomy history. Thompson and colleagues at Mount Sinai specifically identified total lung V20 and mean lung dose as predictors of grade 3 or higher pneumonitis in 40 patients receiving VMAT after P/D.

Esophagitis

Grade 2 or higher esophagitis occurs in 23–49% of patients receiving hemithoracic IMRT, depending on technique. Conventional radiation techniques produced approximately 49% grade 2 or higher esophagitis, while IMRT reduced this to approximately 23%. Proton therapy significantly reduces esophageal dose (mean 26.2 Gy versus 36.9 Gy with IMRT).

Fatigue and Cardiac Effects

Severe protracted fatigue is the most common grade 3 toxicity in multimodality-treated mesothelioma patients, reported in 11–47% across various series. Cardiac toxicity is a concern particularly for left-sided disease. Proton therapy reduces heart mean dose from 25 Gy with IMRT to 6 Gy, a clinically meaningful reduction that may decrease long-term cardiac morbidity.

What Clinical Trials Are Testing Radiation for Mesothelioma?

Several clinical trials are evaluating novel radiation approaches in mesothelioma, reflecting the field's active evolution. Many of these are accessible through mesothelioma clinical trial databases.

Trial	Phase	Design	Status
NRG-LU006 (IMPRINT)	III	P/D + chemo with or without adjuvant IMRT/proton	Terminated Nov 2023
SMARTER (NCT04028570)	I/II	Dose escalation of neoadjuvant RT before surgery	Accruing
SYSTEMS-2	II	20 Gy/5 fractions vs 36 Gy/6 fractions palliative RT	Ongoing
MESO-PRIME (NCT04166734)	II	SABR priming + pembrolizumab	In setup

The NRG-LU006 trial, the only phase III trial specifically testing adjuvant radiation in mesothelioma, was planned to randomize 150 patients to detect an improvement in median overall survival from 12 to 20 months but closed prematurely in November 2023. The 2025 ASCO guideline acknowledges ongoing uncertainty about the benefit of adjuvant hemithoracic radiation.

The convergence of radiation with immunotherapy represents the most active frontier. The immunostimulatory potential of hypofractionated radiation, including the abscopal effect, is being tested in the MESO-PRIME trial combining stereotactic ablative radiotherapy with pembrolizumab. Stereotactic body radiation therapy for oligorecurrent mesothelioma has also shown feasibility, with one series reporting a 12-month local control rate of 73.5% in 21 patients with only 1 grade 3 toxicity.

Frequently Asked Questions

Is mesothelioma resistant to radiation therapy?

No. Despite historical perceptions, laboratory studies demonstrate that mesothelioma cells are similarly or more sensitive to radiation compared to lung cancer cells. The challenge lies in the tumor's location along the pleural surfaces, which makes it difficult to deliver adequate doses without damaging surrounding organs. Modern techniques like IMRT and proton therapy have substantially improved the ability to treat mesothelioma with radiation.

What is the SMART protocol for mesothelioma?

The SMART protocol (Surgery for Mesothelioma After Radiation Therapy) delivers accelerated radiation (25 Gy in 5 fractions) to the affected hemithorax before surgical removal of the lung and pleura. This reversal of the conventional sequence avoids radiation pneumonitis and has produced unprecedented survival results. In epithelioid, node-negative patients, median survival reached 65.9 months — more than 5 years.

Does radiation help with mesothelioma pain?

Yes. Palliative radiation provides symptom relief in approximately 60–80% of mesothelioma patients with chest wall pain or local tumor invasion. Common palliative regimens include 20 Gy in 5 fractions or 30 Gy in 10 fractions. Higher doses appear to produce better symptom control, and the SYSTEMS-2 trial is comparing different dose schedules to optimize palliative outcomes.

Should mesothelioma patients receive radiation to biopsy sites?

Current evidence does not support routine prophylactic irradiation of biopsy or drain tract sites. Although an early French trial in 1995 showed benefit, four subsequent larger randomized trials found no reduction in tract metastases. International guidelines now recommend against prophylactic tract irradiation as standard practice.

What is proton therapy and is it better for mesothelioma?

Proton therapy uses charged particles that deposit energy at a precise depth (the Bragg peak) with minimal exit dose, unlike conventional X-ray radiation. For mesothelioma, this allows dramatic dose reduction to the heart (from 25 Gy to 6 Gy) and contralateral lung (from 4.6 Gy to 0.4 Gy). Clinical data show low toxicity rates, though the evidence base remains small. The NRG-LU006 trial accepted proton therapy as an alternative to IMRT.

Is radiation used for peritoneal mesothelioma?

Radiation plays a very limited role in peritoneal mesothelioma. The standard curative-intent treatment is cytoreductive surgery combined with heated intraperitoneal chemotherapy (CRS-HIPEC). Radiation may be used palliatively for focal symptomatic areas such as port sites or abdominal wall invasion, but whole-abdomen radiation is rarely employed due to toxicity concerns.

What are the main risks of radiation therapy for mesothelioma?

The primary risk is radiation pneumonitis (lung inflammation), which can range from mild to fatal depending on technique and dose constraints. Other side effects include esophagitis (throat/chest pain with swallowing), fatigue, and potential cardiac effects. Modern techniques like IMRT and proton therapy have substantially reduced these risks through precise dose shaping and strict organ-at-risk constraints.

Related Pages

• Mesothelioma Treatment Options
• Chemotherapy for Mesothelioma
• Immunotherapy for Mesothelioma
• Mesothelioma Surgery Overview
• Pleurectomy and Decortication
• Heated Chemotherapy (HITHOC and HIPEC)
• Mesothelioma Clinical Trials
• Mesothelioma Treatment Centers
• Mesothelioma Specialists
• Pleural Mesothelioma
• Peritoneal Mesothelioma
• Mesothelioma Survival Statistics
• Mesothelioma Diagnosis and Staging

⚠ Statute of Limitations Warning: Filing deadlines vary by state from 1-6 years from diagnosis. Texas allows 2 years from diagnosis or discovery. Contact an attorney immediately to preserve your rights.

Free, Confidential Case Evaluation Call (866) 222-9990 or visit dandell.com/contact-us No upfront fees • Experienced representation • National practice